Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Reaffirmed by HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $37.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 38.27% from the company’s previous close.

A number of other analysts have also recently issued reports on ELVN. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Robert W. Baird assumed coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target for the company.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded up $1.22 during midday trading on Tuesday, reaching $26.76. 168,941 shares of the company traded hands, compared to its average volume of 253,850. Enliven Therapeutics has a twelve month low of $9.80 and a twelve month high of $27.67. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -13.79 and a beta of 1.09. The company has a fifty day moving average price of $23.14 and a 200 day moving average price of $21.71.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, equities research analysts forecast that Enliven Therapeutics will post -1.98 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $24.92, for a total transaction of $299,040.00. Following the completion of the transaction, the chief executive officer now directly owns 1,063,525 shares in the company, valued at approximately $26,503,043. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Benjamin Hohl sold 4,250 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.54, for a total value of $95,795.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samuel Kintz sold 12,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $24.92, for a total value of $299,040.00. Following the completion of the transaction, the chief executive officer now owns 1,063,525 shares in the company, valued at approximately $26,503,043. The disclosure for this sale can be found here. Insiders have sold a total of 119,555 shares of company stock valued at $2,972,270 over the last 90 days. 29.20% of the stock is owned by company insiders.

Institutional Trading of Enliven Therapeutics

Large investors have recently bought and sold shares of the company. Quest Partners LLC increased its holdings in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Enliven Therapeutics by 67.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after purchasing an additional 8,540 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in Enliven Therapeutics in the 1st quarter worth $167,000. Finally, Rhumbline Advisers increased its stake in Enliven Therapeutics by 29.9% in the 2nd quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after buying an additional 11,420 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.